- Home
- SOS vs ALLK Comparison
SOS vs ALLK Comparison
Compare SOS & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOS
- ALLK
- Stock Information
- Founded
- SOS 2004
- ALLK 2012
- Country
- SOS China
- ALLK United States
- Employees
- SOS N/A
- ALLK N/A
- Industry
- SOS Finance: Consumer Services
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- SOS Finance
- ALLK Health Care
- Exchange
- SOS Nasdaq
- ALLK Nasdaq
- Market Cap
- SOS 21.7M
- ALLK 22.5M
- IPO Year
- SOS 2017
- ALLK 2018
- Fundamental
- Price
- SOS $6.09
- ALLK $0.29
- Analyst Decision
- SOS
- ALLK Hold
- Analyst Count
- SOS 0
- ALLK 3
- Target Price
- SOS N/A
- ALLK $2.00
- AVG Volume (30 Days)
- SOS 18.4K
- ALLK 5.6M
- Earning Date
- SOS 09-24-2024
- ALLK 03-13-2025
- Dividend Yield
- SOS N/A
- ALLK N/A
- EPS Growth
- SOS N/A
- ALLK N/A
- EPS
- SOS N/A
- ALLK N/A
- Revenue
- SOS $111,124,000.00
- ALLK N/A
- Revenue This Year
- SOS N/A
- ALLK N/A
- Revenue Next Year
- SOS N/A
- ALLK N/A
- P/E Ratio
- SOS N/A
- ALLK N/A
- Revenue Growth
- SOS N/A
- ALLK N/A
- 52 Week Low
- SOS $5.70
- ALLK $0.23
- 52 Week High
- SOS $60.57
- ALLK $1.69
- Technical
- Relative Strength Index (RSI)
- SOS 37.44
- ALLK 33.29
- Support Level
- SOS $5.70
- ALLK $0.28
- Resistance Level
- SOS $6.30
- ALLK $0.33
- Average True Range (ATR)
- SOS 0.39
- ALLK 0.02
- MACD
- SOS -0.00
- ALLK 0.03
- Stochastic Oscillator
- SOS 30.23
- ALLK 55.70
About SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of big data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other service. The company has has three reporting segments: Commodity trading, Cryptocurrency mining and Others. Key revenue is generated from Commodity trading.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.